[1]郑仁东,茅晓东,张会峰,等.IL-6联合sIL-6R对人甲状腺细胞增殖 及相关基因表达的影响[J].国际内分泌代谢杂志,2017,37(02):82-85.[doi:10.3760/cma.j.issn.1673-4157.2017.02.003]
　Zheng Rendong,Mao Xiaodong,Zhang Huifeng,et al.Effects of IL-6 plus sIL-6R on cell proliferation and expression of related genes in human thyroid cells[J].International Journal of Endocrinology and Metabolism,2017,37(02):82-85.[doi:10.3760/cma.j.issn.1673-4157.2017.02.003]
点击复制

IL-6联合sIL-6R对人甲状腺细胞增殖 及相关基因表达的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年02期
页码:
82-85
栏目:
论著
出版日期:
2017-03-20

文章信息/Info

Title:
Effects of IL-6 plus sIL-6R on cell proliferation and expression of related genes in human thyroid cells
作者:
郑仁东; 茅晓东; 张会峰; 曹琳; 孙洪平; 刘超
210028 南京中医药大学附属中西医结合医院内分泌代谢病院区,江苏省中医药研究院
Author(s):
Zheng Rendong;  Mao Xiaodong;  Zhang Huifeng;  Cao Lin;  Sun Hongping;  Liu Chao.
Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, China
关键词:
白细胞介素-6;  可溶性白细胞介素-6受体;  甲状腺细胞;  增殖;  基因;  炎症
Keywords:
Interleukin-6;  Soluble interleukin-6 receptor;  Thyroid cells;  Proliferation;  Gene;  Inflammation
DOI:
10.3760/cma.j.issn.1673-4157.2017.02.003
摘要:
目的 探讨白细胞介素-6(IL-6)联合可溶性IL-6受体(sIL-6R)对人甲状腺细胞增殖及相关基因表达的影响。方法 通过手术标本获得甲状腺组织,采用甲状腺细胞培养技术,提取并培养甲状腺细胞。以不同浓度(0、1、5、10、20 μg/L)的IL-6分别联合sIL-6R 100 μg/L干预细胞24、48 h,予以IL-6单克隆抗体进行阻断。以MTT法检测IL-6干预后的细胞活力,并在显微镜下观察细胞形态学变化; 以RT-PCR测定IL-6、IL-6受体及糖蛋白130的表达,实时定量PCR检测IL-6干预后甲状腺细胞的钠-碘转运体(NIS)、甲状腺过氧化物酶(TPO)、甲状腺球蛋白(TG)、促甲状腺激素受体(TSHR)基因的表达。结果 甲状腺细胞表达IL-6、糖蛋白130,但几乎不表达IL-6受体。IL-6联合sIL-6R培养24、48 h后,甲状腺细胞活力显著增加(F=65.28、78.47; P均<0.05),而使用IL-6单克隆抗体进行阻断,发现随着IL-6单克隆抗体浓度的增加,甲状腺细胞活性亦显著下降(F=60.15,P<0.05); 随着IL-6浓度的增加,甲状腺细胞数量越多,体积越大。IL-6能够抑制NIS、TPO、TG基因的表达(t=6.92～12.12, P均<0.05),而对TSHR基因无明显影响。结论 IL-6联合sIL-6R能够促进甲状腺细胞增殖,同时也能够抑制甲状腺相关基因的表达。
Abstract:
Objective To investigate the effects of interleukin-6(IL-6)and soluble interleukin-6 receptor(sIL-6R)on cell proliferation and related genes expression in human thyroid cells. Methods Thyroid tissues were obtained by surgery, and the thyroid cells were isolated and cultured by thyroid culture technology. Cells were cultured with different concentrations of IL-6(0, 1, 5, 10, 20 μg/L, respectively )plus 100 μg/L sIL-6R for 24 or 48 h. Cell viability was detected by MTT method after blocked by IL-6 monoclonal antibody in thyroid cells. The expression of IL-6, IL-6 receptor and glycoprotein 130 were detected by RT-PCR. The gene expression of sodium iodide transporter(NIS), thyroid peroxidase(TPO), thyroglobulin(TG)and thyroid stimulating hormone receptor(TSHR)were detected by real-time quantitative PCR. Results Thyroid cells expressed IL-6, glycoprotein 130 but not IL-6 receptor. IL-6 plus sIL-6R increased the viability of thyroid cell after 24 h, 48 h(F=65.28, 78.47; all P<0.05), but IL-6 monoclonal antibody decreased the cell activity in dose dependent manner(F=60.15,P<0.05). With the increase of IL-6 concentration, the cell number and volume increased. IL-6 inhibited the gene expression of NIS, TPO and TG(t=6.92-12.12, all P<0.05), but not TSHR. Conclusion IL-6 plus sIL-6R can promote the proliferation of thyroid cells, but also can inhibit the expression of genes in thyroid cells.

参考文献/References:

[1] Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer[J].Cytokine,2010,50(3):229-233. DOI: 10.1016/j.cyto.2010.03.005.
[2] Linkov F, Ferris RL, Yurkovetsky Z,et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases[J].Proteomics Clin Appl,2008,2(12):1575-1585. DOI:10.1002/prca.200780095.
[3] Yamazaki K, Yamada E, Kanaji Y,et al. Interleukin-6(IL-6)inhibits thyroid function in the presence of soluble IL-6 receptor in cultured human thyroid follicles[J].Endocrinology,1996,137(11):4857-4863.
[4] 兰玲,崔岱,施秉银,等.人甲状腺成体干细胞的分离、培养及诱导分化[J].中华医学杂志,2012,92(12):806-810.DOI:10.3760/cma.j.issn.0376-2491.2012.12.005.
[5] 李红林, 高美华, 郑云会,等. 细胞因子IFN-γ、IL6、IL-17和TGF-β1在Graves病发病中的作用[J].中国免疫学杂志, 2015(2): 253-256. DOI:10.3969/j.issn.1000-484X.2015.02.022.
[6] Siemińska L, Wojciechowska C, Kos-Kuda B,et al. Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto's thyroiditis[J].Endokrynol Pol,2010,61(1):112-116.
[7] Provatopoulou X, Georgiadou D, Sergentanis TN,et al. Interleukins as markers of inflammation in malignant and benign thyroid disease[J].Inflamm Res,2014,63(8):667-674. DOI: 10.1007/s00011-014-0739-z.
[8] Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6[J].Int J Biol Sci,2012,8(9):1237-1247. DOI: 10.7150/ijbs.4989.
[9] Murai H, Murakami S, Ishida K,et al. Elevated serum interleukin-6 and decreased thyroid hormone levels in postoperative patients and effects of IL-6 on thyroid cell function in vitro[J]. Thyroid,1996,6(6):601-606. DOI:10.1089/thy.1996.6.601.
[10] Nielsen CH, Brix TH, Leslie RG,et al. A role for autoantibodies in enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase[J].Clin Immunol,2009,133(2):218-227. DOI: 10.1016/j.clim.2009.07.014.
[11] Papanas N, Papazoglou D, Papatheodorou K,et al. Thyroxine replacement dose in patients with Hashimoto disease: a potential role for interleukin-6[J]. Cytokine,2006,35(3-4):166-170. DOI:10.1016/j.cyto.2006.07.017.

相似文献/References:

[1]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
　Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(02):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]

备注/Memo

备注/Memo:
通信作者:刘超,Email:liuchao@nfmcn.com
更新日期/Last Update: 2017-03-20